Compare HubSpot Inc (HUBS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs 10X Genomics Inc — how do they compare? HubSpot Inc trades at $208.36 (market cap $11.00B), while 10X Genomics Inc trades at $57.02 (market cap $7.61B). The key difference: HubSpot Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| HUBS | TXG | |
|---|---|---|
Market Cap | $11.00B | $7.61B |
Sector | Technology | Health |
52-Week High | $522.97 | $58.57 |
52-Week Low | $170.39 | $11.34 |
Enterprise Value | $9.89B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $210.92, down 2.31% on the day, amid a bearish technical signal and recent stock volatility following Q2 2026 results. The company reported strong earnings beats but lowered its customer-growth forecast, contributing to a sharp price decline from previous highs. Revenue growth remains robust at 20% year-over-year, yet high valuation multiples and margin pressures present challenges. Analyst sentiment is predominantly bullish with a $233.93 consensus target, but near-term execution risks and increased AI spending weigh on investor confidence.
The outlook for HUBS hinges on successful execution of its AI-driven strategy amid slower customer acquisition. Investment opportunity lies in its solid revenue growth and market position if it can navigate budget scrutiny and competitive pressures. Key risks include heightened execution risks, potential securities litigation, and the financial impact of strategic shifts, which could limit near-term upside despite long-term transformation potential.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
